105 related articles for article (PubMed ID: 2142395)
1. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
[TBL] [Abstract][Full Text] [Related]
2. Acute endocrine effects of interleukin-12 in cancer patients.
Lissoni P; Rovelli F; Rivolta MR; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G
J Biol Regul Homeost Agents; 1997; 11(4):154-6. PubMed ID: 9582616
[TBL] [Abstract][Full Text] [Related]
3. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
[TBL] [Abstract][Full Text] [Related]
4. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
5. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
6. Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients.
Chambrier C; Mercatello A; Tognet E; Cottet-Emard JM; Cohen R; Blay JY; Favrot M; Philip T; Beylot M
J Biol Response Mod; 1990 Apr; 9(2):251-5. PubMed ID: 2341864
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.
Lissoni P; Rovelli F; Tancini G; Tisi E; Rivolta MR; Ardizzoia A; Brivio F
J Biol Regul Homeost Agents; 1992; 6(4):113-5. PubMed ID: 1338354
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients.
Lissoni P; Barni S; Rovelli F; Crispino S; Fumagalli G; Pescia S; Vaghi M; Camesasca G; Tancini G
Tumori; 1991 Jun; 77(3):212-5. PubMed ID: 1862547
[TBL] [Abstract][Full Text] [Related]
9. Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication).
Crispino S; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Tancini G
J Biol Regul Homeost Agents; 1992; 6(4):142-4. PubMed ID: 1296456
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
14. Age-related changes of neuro-endocrine-immune interactions in healthy humans.
Mazzoccoli G; Correra M; Bianco G; De Cata A; Balzanelli M; Giuliani A; Tarquini R
J Biol Regul Homeost Agents; 1997; 11(4):143-7. PubMed ID: 9582614
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
16. Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E
J Biol Regul Homeost Agents; 2005; 19(3-4):141-4. PubMed ID: 16602629
[TBL] [Abstract][Full Text] [Related]
17. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
Eastman ME; Khorsand M; Maki DG; Williams EC; Kim K; Sondel PM; Schiller JH; Albertini MR
Cancer; 2001 Feb; 91(4):806-14. PubMed ID: 11241250
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
19. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
20. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
